2. Academic Validation
  3. Novel Compounds as LPAR1 Inhibitors for Treating Systemic Sclerosis

Novel Compounds as LPAR1 Inhibitors for Treating Systemic Sclerosis

  • ACS Med Chem Lett. 2026 Jan 2;17(2):296-297. doi: 10.1021/acsmedchemlett.5c00764.
Ram W Sabnis 1
Affiliations

Affiliation

  • 1 Arclin USA LLC, 1150 Sanctuary Parkway, Suite 100, Alpharetta, Georgia 30009, United States.
PMID: 41704368 DOI: 10.1021/acsmedchemlett.5c00764
Abstract

Provided herein are novel compounds as LPAR1 inhibitors, pharmaceutical compositions, use of such compounds in treating systemic sclerosis, and processes for preparing such compounds.

Figures